FIGURE 5.

Inhibition of PDPK1 enhances docetaxel sensitivity in PCa cells. A, The PCa cells were treated with docetaxel, GSK2334470 and BX795 for 72 h, followed by evaluation of cell viability. Each data point represents mean ± SD of at least three independent experiments. B, Synergistic effects of PDPK1 inhibitors (GSK2334470 and BX795) and docetaxel in DU145, PC3 and LNCaP cells. PCa cells were treated with docetaxel and/or PDPK1 inhibitors for 72 h. The dose‐response surface curves with HSA synergy/antagonism of the combinations were generated by Combenefit software. ²⁶ A colour scale bar is used to indicate the level of synergism (blue) or antagonism (red) for each combination. All experiments were conducted at least three times